Enzo Biochem, Inc. ($0.01 Par Value)
Enzo Biochem, Inc. ($0.01 Par Va.../ US2941001024 /
ENZ
12/10/2019 8:54:44 PM
|
Chg.
+0.07
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
2.69USD
|
+2.48%
|
492 Turnover: 1,298.44 |
-Bid Size: - |
-Ask Size: - |
135.54 mill.USD |
0.00% |
- |
Business description
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Management board & Supervisory board
CEO |
Dr. Elazar Rabbani |
Management board |
Barry W. Weiner, Dieter Schapfel, James M. O'Brien, Kara Cannon, Paul O’Brien |
Supervisory board |
Dr. Elazar Rabbani, Barry W. Weiner, Dov Perlysky, Dr. Bruce A. Hanna, Gregory M. Bortz |
Company data
Name: |
Enzo Biochem Inc. |
Address: |
527 Madison Avenue,New York, New York 10022, USA |
Phone: |
+1-212-583-0100 |
Fax: |
+1-212-679-7999 |
E-mail: |
info@enzo.com
|
Internet: |
www.enzo.com |
Industry: |
Biotechnology |
Sector: |
Biotechnology |
Sub sector: |
Biotechnology |
End of financial year: |
7/31 |
Free Float: |
53.20% |
IPO date: |
- |
Main Shareholders
Freefloat |
|
53.20% |
Evermore Global Advisors LLC |
|
9.70% |
Blackrock Fund Advisors |
|
8.50% |
Wellington Management Group LLP |
|
8.20% |
Renaissance Technologies, LLC |
|
6.30% |
The Vanguard Group Inc. |
|
5.80% |
Elazar Rabbani |
|
3.90% |
Barry W. Weiner |
|
2.70% |
Dov Perlysky |
|
1.70% |